Insights from Meet-URO 23/I-RARE: Prognostic Factors and Clinical Outcomes in PSCC

By Veronica Mollica, MD - Last Updated: April 19, 2024

Veronica Mollica, MD, of the University of Bologna, highlights her recent research investigating prognostic factors and clinical outcomes for patients with penile squamous cell carcinoma.

Dr. Mollica details the key prognostic factors associated with OS and PFS as identified through univariate and multivariate analysis as well as how these factors help in predicting the outcomes of PSCC patients.

Evaluating Cemiplimab in la/mPC: New Findings From the Phase II EPIC-A Trial

Emily MenendezTesticular, Penile, and Rare Malignancies | February 13, 2025

The EPIC-A trial has demonstrated the efficacy and safety of cemiplimab combined with platinum-based chemotherapy for la/mPC.

Retroperitoneal Lymph Node Metastasis in Testicular Cancer: MRI, CT Show Comparable Accuracy

Emily MenendezTesticular, Penile, and Rare Malignancies | February 7, 2025

Specificity findings varied, but some studies suggested similar or slightly higher rates in favor of MRI.

First-Line PD-1 Blockade, Cisplatin, Paclitaxel Effective for Advanced PSCC in Retrospective Study

Emily MenendezTesticular, Penile, and Rare Malignancies | January 18, 2025

There is a lack of data on 1L regimens for distant metastatic PSCC, with a 2-year OS rate of just 21%.

Challenges in Treating Penile Cancer

Andrea Necchi, MDTesticular, Penile, and Rare Malignancies | September 16, 2024

Drs. Necchi and Tawagi highlight some the challenges in penile cancer, including "suboptimal" neoadjuvant, adjuvant options.

TIP Combination Provides 5-Year OS, PFS Benefits for Second-Line GCTs

Emily MenendezTesticular, Penile, and Rare Malignancies | August 1, 2024

Paclitaxel, ifosfamide, and cisplatin is a combination commonly used for the treatment of germ cell tumors.

Insights from Meet-URO 23/I-RARE: Prognostic Factors and Clinical Outcomes in PSCC

Related Posts